The Calm-CAH Study is currently enrolling adults 18 to 74 years of age diagnosed with classic congenital adrenal hyperplasia (CAH). To learn more and see if you may be eligible to take part, visit CrineticsCAH.com/CARES.

What You Should Know About Clinical Research Studies

Clinical research studies, also called clinical trials, aim to answer specific questions about how medicines work in the volunteers who take them. You should feel fully informed about what to expect from your participation in a clinical research study.

Researchers use clinical research studies to:

- Learn about the safety and effects of investigational medicines
- Help find new ways of using certain medications
- Answer specific health questions

Participation in any study is voluntary, and you can choose to end your participation at any time and for any reason. The study team will inform you of the potential risks and benefits of study participation, as well as possible side effects. To make an informed decision, talk to your healthcare providers about any questions you may have.

All clinical research studies are:

- Developed to protect the rights, safety, and well-being of participants
- Conducted according to strict scientific and ethical principles
- Reviewed and approved by an institutional review board (IRB) or ethics committee (EC)

It is important to note that not everyone may be a candidate for a clinical research study, but other options could be available. Those who may not qualify are encouraged to discuss next steps with their doctor.

Thank you for considering the Calm-CAH Study.

To learn more or to see if you may qualify for the Calm-CAH Study, scan the QR code or visit **CrineticsCAH.com/CARES**.

CRN04894-12_Recruitment Brochure_CARES_V1_07/2025_NP-CAH-0093-2
CAL-ENUS-CARBR-V1-5SEP25

A CLINICAL RESEARCH STUDY OF A POTENTIAL NEW TREATMENT FOR ADULTS LIVING WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH)

Are You Facing Challenges Due to CAH?

Consider Joining a Clinical Research Study

Crinetics Pharmaceuticals

Calm-CAH

About the Study

The Calm-CAH Study is evaluating the safety and effectiveness of an investigational study drug, atumelnant, whether it may reduce the dosage needed for steroid medications like glucocorticoids (GCs), and how it may help manage symptoms of congenital adrenal hyperplasia (CAH).

The study will last about 10 months with up to 14 study visits, 4 of which may be done by telephone.

You will be randomly assigned, like drawing straws, to receive the study drug or a placebo, which is a substance that looks just like the study drug but does not contain any medicine.

You will have a higher chance of receiving the study drug (about 66%) than the placebo (about 33%).

Throughout the study, you will be able to remain on your GCs as directed by your physician, but efforts will be made to reduce the dosage needed, based on how you are feeling. A team of medical professionals will monitor your health throughout the study.

The assigned study treatment is a tablet that will be taken orally once daily in the evening as instructed by your study doctor.

The assigned study treatment, study lab tests, imaging (DXA scan [bone density test], ultrasound in male participants, and optional CT scan), study procedures, and safety assessments are provided at no cost to you. Additionally, reasonable costs for travel may be reimbursed when you visit the research center for study visits.

If you complete the Calm-CAH Study, you may be eligible to enroll in a long-term extension study where you will be guaranteed to receive the study drug, even if you previously received the placebo in the Calm-CAH Study.

About the Study Drug

CAH causes the body's adrenal glands to stop producing enough hormones like cortisol (helps the body's response to stress) and aldosterone (regulates blood pressure in the body), causing the overproduction of androgens (male sex hormones).

The study drug, which is an oral tablet, is designed to help the body establish a more normal level of hormone production by directly and specifically targeting the malfunctioning adrenal gland.

In a previous phase 2 study for adults living with CAH caused by 21-hyroxylase deficiency or classic CAH, after 12 weeks of receiving the study drug, atumelnant, all 3 doses saw a reduction of the hormones that contribute to CAH. In that study, atumelnant was generally well tolerated, and the most common side effects included headache (in 7 patients) and fatigue (in 5 patients). The study enrolled 28 patients across 3 dose cohorts with classic CAH on a stable dose of glucocorticoid replacement.[1]

Researchers believe that atumelnant has the potential to reduce the need for excessive doses of GCs.

Atumelnant is an investigational study drug, which means it has not been approved by any regulatory authority and is still under investigation as a potential treatment for CAH. It can only be used in research studies like this one.

You will receive the same level of care from the study team regardless of whether you are receiving the study drug or placebo.

1. crinetics.com/crinetics-announces-positive-topline-results-from-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia-cah

Study Schedule

The Calm-CAH Study is made up of the following periods:

- **Screening period:** The study team will perform assessments, such as blood and urine sample collections, to make sure the study is a good match for you. There will be 2 screening visits at the research center.
- **Treatment period:** If you qualify and decide to participate, you will take your assigned study treatment once daily in the evening. There will be 10 study visits, 3 of which may be completed by telephone.
  - If you complete the treatment period, you may be eligible to enroll in a long-term extension study where you are guaranteed to receive the study drug, even if you previously received the placebo in the Calm-CAH Study.
- **Follow-up period:** You will stop taking your assigned study treatment and have 2 follow-up visits so the study team can monitor your health. One visit may be completed by telephone.
  - This period is not required if you enter the long-term extension study.

Screening	Treatment	Follow-Up
Up to 6 weeks 2 visits	Up to 7.5 months 7 visits, 3 phone calls	Up to 4 weeks 1 visit, 1 phone call

Study Requirements

If you are interested in joining the study, you must:

- Be 18 to 74 years of age
- Have received a diagnosis of classic CAH
- Be on a stable GC regimen (for example: modified-release hydrocortisone, cortisone acetate, prednisolone, prednisone, methylprednisolone, dexamethasone)

Additional requirements apply, which the study team will discuss with you.